CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study
First challenge infection study in preclinical mouse model to provide evidence for protection against SARS-CoV-2 variantCVnCoV induces robust antibody titers...